Reference is made to the stock exchange announcement from Navamedic ASA (the «Company») on 13 February 2019 regarding the Company’s acquisition of Novicus Pharma AS. The Company has today completed the acquisition of Novicus Pharma AS.

In connection with the acquisition, the board of directors in the Company has resolved to issue 1,000,000 new shares in the Company at a price of NOK 11.67 per new share. The new shares are issued as consideration to the sellers of Novicus Pharma AS pursuant to an authorization granted by the Company’s annual general meeting on 7 June 2018. Following registration of the share capital increase with the Norwegian Register of Business Enterprises, the Company’s new share capital will be NOK 11,867,673, divided on 11,867,673 shares, each with a nominal value of NOK 1.   

For further information, please contact:

Toril Ås

Chief Financial Officer (CFO)

Navamedic ASA

Tel: +47 95 70 10 71

E-mail: toril.as@navamedic.com  

This information is subject of the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.